Publications
164
Citations
6,059
Est. group size
—
Recurring co-author estimate
Active years
37
Publishing since 1988
Typically publishes in teams of ~18 · 8% small-team papers (≤3 authors) · across 16 venues
- Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment <sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Stage III Non–Small Cell Lung Cancer
Journal of Clinical Oncology · 2024
- PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0
European Journal of Nuclear Medicine and Molecular Imaging · 2023
- Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE)
European Urology · 2023
- Diagnostic Performance and Safety of <sup>18</sup> F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT)
The Journal of Urology · 2023
- Figure S1 from Diagnostic Performance of <sup>18</sup>F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study
2023
- Supplementary Appendix from Diagnostic Performance of <sup>18</sup>F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study
2023
- Figure S2 from Diagnostic Performance of <sup>18</sup>F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study
2023
- Data from Diagnostic Performance of <sup>18</sup>F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study
2023
- Data from Diagnostic Performance of <sup>18</sup>F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study
2023
- Figure S1 from Diagnostic Performance of <sup>18</sup>F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study
2023
- Figure S2 from Diagnostic Performance of <sup>18</sup>F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study
2023
- Supplementary Appendix from Diagnostic Performance of <sup>18</sup>F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study
2023
- Synthesis of 68Ga-radiopharmaceuticals using both generator-derived and cyclotron-produced 68Ga as exemplified by [68Ga]Ga-PSMA-11 for prostate cancer PET imaging
Nature Protocols · 2022
- Prostate Cancer With Peritoneal Carcinomatosis: A Robotic-assisted Radical Prostatectomy-based Case Series
Urology · 2022
- Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study
Clinical Cancer Research · 2021
- Journal of Nuclear Medicine×8
- Journal of Clinical Oncology×7
- International Journal of Radiation Oncology*Biology*Physics×4
- The Journal of Urology×2
- Research Square×2
- Daniel J. Wale
Medicine · University of Michigan
- Frey Ka
Medicine · University of Michigan
- Avery Peterson
Medicine · University of Michigan
- Zirui Jiang
Medicine · Purdue University West Lafayette
- Zhonglin Lu
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile